WO2003105772A3 - PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS - Google Patents

PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS Download PDF

Info

Publication number
WO2003105772A3
WO2003105772A3 PCT/US2003/018890 US0318890W WO03105772A3 WO 2003105772 A3 WO2003105772 A3 WO 2003105772A3 US 0318890 W US0318890 W US 0318890W WO 03105772 A3 WO03105772 A3 WO 03105772A3
Authority
WO
WIPO (PCT)
Prior art keywords
parathyroid hormone
anabolizing
bone
agents
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018890
Other languages
French (fr)
Other versions
WO2003105772A2 (en
Inventor
Michael Chorev
Michael Rosenblatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Priority to US10/516,224 priority Critical patent/US7799757B2/en
Priority to AU2003251527A priority patent/AU2003251527A1/en
Priority to EP03760386A priority patent/EP1551438A2/en
Publication of WO2003105772A2 publication Critical patent/WO2003105772A2/en
Publication of WO2003105772A3 publication Critical patent/WO2003105772A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux analogues d'hormone parathyroïde et de nouveaux analogues de protéine liée à l'hormone parathyroïde. L'invention concerne également des procédés d'utilisation de ces analogues pour traiter l'ostéoporose, promouvoir la formation osseuse et inhiber la perte osseuse.The present invention relates to novel analogs of parathyroid hormone and novel analogs of protein linked to parathyroid hormone. The invention also relates to methods of using these analogs to treat osteoporosis, promote bone formation and inhibit bone loss.

PCT/US2003/018890 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents Ceased WO2003105772A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/516,224 US7799757B2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
AU2003251527A AU2003251527A1 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
EP03760386A EP1551438A2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38891802P 2002-06-13 2002-06-13
US60/388,918 2002-06-13
US39800502P 2002-07-23 2002-07-23
US60/398,005 2002-07-23

Publications (2)

Publication Number Publication Date
WO2003105772A2 WO2003105772A2 (en) 2003-12-24
WO2003105772A3 true WO2003105772A3 (en) 2004-04-08

Family

ID=29740073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018890 Ceased WO2003105772A2 (en) 2002-06-13 2003-06-13 Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Country Status (4)

Country Link
US (1) US7799757B2 (en)
EP (1) EP1551438A2 (en)
AU (1) AU2003251527A1 (en)
WO (1) WO2003105772A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN101355959B (en) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 Black bear parathyroid hormone and methods of using black bear parathyroid hormone
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
KR101512377B1 (en) * 2006-10-03 2015-04-28 라디우스 헬쓰, 인코포레이티드 Method of drug delivery for bone anabolic protein
AU2007313001B2 (en) 2006-10-13 2012-03-22 Eli Lilly And Company Pegylated PTH as PTH receptor modulators and uses thereof
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2568806B1 (en) 2010-05-12 2016-05-11 Radius Health, Inc. Therapeutic regimens
CN102399285B (en) * 2011-05-31 2014-06-04 成都金凯生物技术有限公司 Parathyroid hormone (PTH) derivative
CN102993293B (en) * 2012-12-05 2014-05-07 深圳翰宇药业股份有限公司 Method for purifying teriparatide acetate
WO2014209893A2 (en) * 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
FI3834824T3 (en) 2014-03-28 2025-12-05 Univ Duke TREATMENT OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER WITH SELECTIVE ESTROGEN RECEPTOR MODULATOR
JP7019422B2 (en) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド How to treat cancer
LT3474841T (en) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
KR102707399B1 (en) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
CN113348163B (en) 2019-02-12 2024-10-08 雷迪厄斯制药公司 Methods and compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288253B2 (en) 2003-08-08 2007-10-30 Amgen Fremont, Inc. Antibodies directed to parathyroid hormone (PTH) and uses thereof

Also Published As

Publication number Publication date
WO2003105772A2 (en) 2003-12-24
US7799757B2 (en) 2010-09-21
US20060058230A1 (en) 2006-03-16
AU2003251527A8 (en) 2003-12-31
AU2003251527A1 (en) 2003-12-31
EP1551438A2 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
WO2003105772A3 (en) PARATHYROID HORMONE ANALOGS AND PARATHYROID HORMONE-RELATED PROTEIN AS BONE ANABOLIZING AGENTS
LT2001004A (en) Fertilizer from sapropel and manufacture thereof
BG102726A (en) Combined therapy for osteoporosis
BR0307702A (en) Antibody-containing solution formulations
EP0911321A3 (en) Compounds for the treatment of osteoporosis
BR0114630A (en) Growth Hormone Secretagogues
BR9812837A (en) Process for making a compound, and, compound
EP1404324A4 (en) PROMOTERS OF GABA ANALOGS, COMPOSITIONS AND USES OF SAID PROMEDICAMENTS
NO20034230D0 (en) 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
WO1998058911A3 (en) Prostaglandin agonists
BR0213355A (en) pharmaceutical compositions
CA2294078A1 (en) C-peptide specific assay procedure
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
PL374080A1 (en) Processes for the preparation of fibrinogen
ATE202483T1 (en) IMMUNTOLERANT PROTHROMBIN COMPLEX PREPARATION
DE60233803D1 (en) 5-CNAC FOR ORAL ADMINISTRATION OF PARATHORMONE FRAGMENTS
BR9808923A (en) Compound, and, process to do the same
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
BR0207066A (en) 2h-1-benzopyran derivatives - processes for their preparation and pharmaceutical compositions from them
DE69808475D1 (en) AMINO ACID DERIVATIVES FOR TREATING STROKE
MY147518A (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CA2286296A1 (en) Inhibitors for urokinase receptor
DE50309260D1 (en) PROCESS FOR THE PREPARATION OF BICALUTAMIDE
WO2002032884A3 (en) Methods for the preparation of biphenyl isoxazole sulfonamides
DE60222552D1 (en) CARBAMATES OF 2-HETEROCYCLIC 1,2-ETHANEDIOLS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003760386

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006058230

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10516224

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003760386

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10516224

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760386

Country of ref document: EP